{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-016069","form_type":"8-K","ticker":"FBLG","cik":"0001958777","company_name":"FibroBiologics, Inc.","filed_at":"2024-04-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.309016+00:00","generated_at":"2026-06-03T06:45:25.453658+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"FibroBiologics pipeline update: CYWC628 pre-clinical data shows improved wound healing vs Grafix","bullets":["CYWC628 multiple administration study: 69.3% wound area reduction at day 12 vs 47.13% for Grafix (p<0.05).","Planning Phase 1/2 clinical trial in Australia for diabetic foot ulcers in 2025, results expected Q3 2025.","FDA IND clearance for CybroCell Phase 1/2 trial for degenerative disc disease, conditional on master cell bank.","Expect to complete remaining CYWC628 pre-clinical studies (toxicity, dose titration) in Q3 2024.","Manufacturing: planning CDMO transfer; master cell bank, working cell bank, and drug product by end of 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-016069","json":"https://secwatch.observer/filing/0001493152-24-016069.json","markdown":"https://secwatch.observer/filing/0001493152-24-016069.md","text":"https://secwatch.observer/filing/0001493152-24-016069.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1958777/000149315224016069/0001493152-24-016069-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1958777/000149315224016069/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T06:45:25.453658+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}